News
Short-course fluoroquinolone treatment is as effective as the conventional 7-day course for acute exacerbations of chronic ...
6d
Stars Insider on MSNWhat is chronic obstructive pulmonary disease?According to the World Health Organization (WHO), chronic obstructive pulmonary disease (COPD) is the third leading cause of ...
Chronic respiratory illnesses affect millions. Learn how PCPs can effectively manage asthma, COPD, and allergies through ...
As per the agreement, SUP will obtain regulatory approvals for selling Tiotropium DPI in China, while Lupin will be the ...
People with one of more than 20 breathing conditions could be eligible for up to £749 a month from the Department for Work ...
New Partnership with Leonard Nimoy’s Daughter Aims to Raise COPD Awareness ...
A 6-minute walk of less than 350 meters tripled the mortality risk, whereas chronic kidney disease (CKD) independently ...
Lupin & Sino Universal Pharmaceuticals ink license and supply agreement for tiotropium DPI in China: Our Bureau, Mumbai Monday, June 16, 2025, 14:30 Hrs [IST] Global pharma major ...
6d
News Medical on MSNScientists find unusual build-up of soot-like particles in lung cells of COPD patientsCells taken from the lungs of people with chronic obstructive pulmonary disease (COPD) have a larger accumulation of ...
11h
Stockhead on MSNDr Boreham’s Crucible: Sizing up the opportunity for ASX biotech AdheriumPlenty folk have an asthma puffer but few seem to know how to use it. Adherium says its Hailie device is improving compliance ...
Lupin partners with SUP to commercialize Tiotropium DPI in China, aiming to improve respiratory health with innovative products.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results